12-May-2026
MannKind Reports First Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Wed, 6-May 4:01 PM ET)
MannKind's Ralinepag DPI Collaboration Points to Transformative Role in Pulmonary Hypertension Care
Market Chameleon (Wed, 6-May 6:30 AM ET)
Globe Newswire (Wed, 6-May 6:30 AM ET)
MannKind to Report First Quarter 2026 Financial Results on May 6, 2026
Globe Newswire (Wed, 29-Apr 4:01 PM ET)
MannKind to Present New Data From Pediatric and Adult Studies of Afrezza at ATTD 2026
Globe Newswire (Mon, 9-Mar 9:05 AM ET)
MannKind Announces Settlement of Convertible Senior Notes
Globe Newswire (Thu, 5-Mar 4:30 PM ET)
MannKind to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Mar 9:00 AM ET)
MannKind Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 26-Feb 8:00 AM ET)
MannKind to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Globe Newswire (Thu, 19-Feb 9:00 AM ET)
MannKind to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Globe Newswire (Wed, 18-Feb 9:00 AM ET)
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
Mannkind trades on the NASDAQ stock market under the symbol MNKD.
As of May 12, 2026, MNKD stock price declined to $3.28 with 5,054,518 million shares trading.
MNKD has a beta of 2.23, meaning it tends to be more sensitive to market movements. MNKD has a correlation of 0.13 to the broad based SPY ETF.
MNKD has a market cap of $995.78 million. This is considered a Small Cap stock.
Last quarter Mannkind reported $90 million in Revenue and -$.02 earnings per share. This fell short of revenue expectation by $-15 million and missed earnings estimates by -$.03.
In the last 3 years, MNKD traded as high as $7.63 and as low as $2.23.
The top ETF exchange traded funds that MNKD belongs to (by Net Assets): XBI, IWM, VTI, IWO, VXF.
MNKD has underperformed the market in the last year with a return of -28.1%, while the SPY ETF gained +32.1%. In the last 3 month period, MNKD fell short of the market, returning -42.9%, while SPY returned +6.9%. However, in the most recent 2 weeks MNKD has outperformed the stock market by returning +24.7%, while SPY returned +3.2%.
MNKD support price is $3.25 and resistance is $3.47 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MNKD shares will trade within this expected range on the day.